The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

ADCs, radiopharmaceuticals, precision medicines and T-cell engagers dominated R&D pipelines reviewed by 12 big pharmas at the first annual AACR Oncology Industry Partnering Event.

Start-up hopes to bring its first candidate, an NY-ESO-1-targeting off-the-shelf product, into the clinic in Q2. Astex and Cardiff University team up on novel therapies for neurodegenerative disease.

Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.